eXoZymes stock analysis
Want to see EXOZ full AI Analyst Report?
eXoZymes (EXOZ) Stock Price & Analysis
EXOZ Stock Chart & Stats
- Day’s Range
- $3.54 - $4.25
- 52-Week Range
- $3.24 - $16.90
- Previous Close
- $4.00
- Volume
- N/A
- Average Volume (3M)
- 13.04K
- Market Cap
- $35.55M
- Enterprise Value
- $51.92M
- Total Cash (Recent Filing)
- $3.26M
- Total Debt (Recent Filing)
- $1.00M
- Price to Earnings (P/E)
- ―
- Beta
- 1.20
- Next Earnings
- N/A
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Moderate Leverage
Current leverage is moderate and has improved from the prior year, reducing near-term debt pressure relative to 2025. This provides some financial flexibility, although the benefit is limited because the company remains loss-making and dependent on external funding.
Improving Free Cash Flow Trend
The improvement in free cash flow versus 2024 suggests some progress in cash management and slows the deterioration in funding needs. However, the ongoing deficit means this is a modest positive rather than evidence of self-sustaining operations or durable internal financing.
Capital Markets Outreach
A standardized investor presentation can improve communication with financial intermediaries and potential investors, supporting more organized financing efforts. Over the next several months, this may enhance fundraising access and stakeholder understanding, even though it does not improve operating results.
Bears Say
No Revenue Base
The absence of revenue means the company has not yet demonstrated commercial traction or operating leverage. It also limits visibility into future cash generation, leaving progress dependent on converting development activity into a viable revenue stream over time.
Widening Losses
Materially wider losses indicate that the expense base is accelerating faster than any operating contribution, since revenue remains absent. Persistent earnings deterioration can increase future financing requirements and makes eventual profitability more difficult to reach without a meaningful change in execution.
Cash Burn And Financing Dependence
Heavy ongoing cash consumption without a revenue base reduces financial durability and requires the company to secure additional capital to fund operations. Continued external financing can constrain strategic flexibility and create dilution risk, particularly while losses remain elevated.
eXoZymes News
eXoZymes announces graduation from Shell GameChanger Accelerator
eXoZymes (EXOZ) announced its graduation from the Shell GameChanger Accelerator, a multimillion-dollar, multiyear program developed in collaboration between Shell and the U.S. Department of Energy’s National Laboratory of the Rockies.
EXOZ FAQ
What was eXoZymes’s price range in the past 12 months?
What is eXoZymes’s market cap?
When is eXoZymes’s upcoming earnings report date?
How were eXoZymes’s earnings last quarter?
Is eXoZymes overvalued?
Does eXoZymes pay dividends?
What is eXoZymes’s EPS estimate?
How many shares outstanding does eXoZymes have?
What happened to eXoZymes’s price movement after its last earnings report?
Which hedge fund is a major shareholder of eXoZymes?
What is the TipRanks Smart Score and how is it calculated?
eXoZymes Stock Smart Score
Company Description
eXoZymes
eXoZymes, Inc. operates as a development stage biotechnology company. It focuses on the development of enzyme modules and cell-free exozyme biosolutions for synthetic biology manufacturing. The company was formerly known as Invizyne Technologies, Inc. and changed its name to eXoZymes, Inc. in February 2025. eXoZymes, Inc. was incorporated in 2014 and is headquartered in Monrovia, California.
- Sector
- General
- Industry
- Biotechnology
- CEO
- Michael Heltzen
- Employees
- 32
- Website
- exozymes.com
- Address
- 750 Royal Oaks Drive, Monrovia, CA, 91016, US
eXoZymes (EXOZ) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 5 | 3 | 14 |
| Technical Analysis | 5 | 3 | 2 |
| Moving Averages | 0 | 0 | 12 |












